Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference
Nautilus Biotechnology, a pioneer in single-molecule protein analysis, will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2022, at 11:05 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nautilus Biotechnology, a pioneer in single-molecule protein analysis, will participate in the Morgan Stanley Global Healthcare Conference on September 12, 2022, at 11:05 a.m. ET. The event will feature a fireside chat with company management, and interested parties can access the live and archived webcast via the Investors section of Nautilus’ website.
Based in Seattle, Nautilus aims to transform proteomics by democratizing access to the proteome, facilitating advancements in human health and medicine.
Details
News Market Reaction – NAUT
The recorded move for NAUT in the trading session of this news was +0.46%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Nautilus’ management is scheduled to participate in a fireside chat on Monday, September 12th at 11:05 a.m. Eastern Time / 8:05 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.nautilus.bio.
About Nautilus Biotechnology, Inc.
Based in Seattle, Washington, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.
Investor Contact
investorrelations@nautilus.bio
Media Contact
press@nautilus.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.